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ContaminantsFlavour ingredients are an essential part of e-liquids. Their responsible selection and inclusion levels in
e-liquids must be guided by toxicological principles. We propose an approach to the screening and tox-
icological risk assessment of ﬂavour ingredients for e-liquids. The screening involves purity requirements
and avoiding ingredients that are carcinogenic, mutagenic or toxic to reproduction. Additionally, owing to
the uncertainties involved in potency determination and the derivation of a tolerable level for respiratory
sensitisation, we propose excluding respiratory sensitisers. After screening, toxicological data on the
ingredients should be reviewed. Inhalation-speciﬁc toxicological issues, for which no reliable safe levels
can currently be derived, can lead to further ingredient exclusions. We discuss the use of toxicological
thresholds of concern for ﬂavours that lack inhalation data suitable for quantitative risk assessment.
Higher toxicological thresholds of concern are suggested for ﬂavour ingredients (170 or 980 lg/day) than
for contaminant assessment (1.5 lg/day). Analytical detection limits for measurements of potential reac-
tion and thermal breakdown products in vaping aerosol, should be informed by the contaminant thresh-
old. This principle leads us to recommend 5 ng/puff as an appropriate limit of detection for untargeted
aerosol measurements.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The main users of e-cigarettes are current smokers, especially
those who have expressed an interest in quitting or cutting down
cigarette consumption. In the same way that the taste of tobacco
is important to cigarette smokers, ﬂavour is an important part of
the e-cigarette experience, including for regular adoption or con-
version. Farsalinos et al. (2013) undertook a survey of 4618
Greek e-cigarette users to assess ﬂavour preferences. The median
duration of smoking cigarettes was 22 years and of e-cigarettes
was 12 months. Respondents reported that having a variety of ﬂa-
vours available was very important to efforts to quit smoking, and
almost half felt that restriction of variety would increase cravings
for cigarettes. The authors concluded that liquid ﬂavourings in
e-cigarettes contribute substantially to the overall experience of
persistent users. Similarly, when adults in the US were surveyed
about their tobacco use and motivations for starting and stopping
e-cigarette use, the study found the most important reason for
stopping vaping was the taste of the product (Biener and
Hargraves, 2014). This feature was particularly important to thosewho had tried e-cigarettes only once or twice, whereas taste
played a notably lesser role in stopping vaping for intensive and
intermittent users. These ﬁndings imply that taste, and hence
ﬂavourings, are likely to play a major role in the difference
between people only trying e-cigarettes versus actually adopting
them for longer term use. Indeed, ﬂavourings might be essential
to smoking cessation in e-cigarettes users, because the US study
concluded that daily use of e-cigarettes for at least 1 month was
strongly associated with quitting smoking after a 2-year
follow-up period, compared with intermittent or no use.
The market for e-cigarettes has expanded extremely quickly
worldwide. Long-term research ﬁndings on the health effects of
vaping are not yet available, and methods for various assessments,
such as toxicology, ﬂavours, respiratory effects and so on, are still
to be agreed upon. However, as vaping products are widely avail-
able, publication, debate and agreement on risk assessment
approaches are becoming increasingly important. Regulations are
still developing and are not yet up to date with vaping reality.
Therefore, industry can help to develop appropriate product stan-
dards and implement robust quality management systems. Much
of the focus of studies reported thus far has been related to the risk
assessment of the solvents and nicotine in e-liquid. Additionally,
screening and risk assessment considerations are generally
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main consumer exposure to the e-liquid during normal use is to
the aerosol. In this paper we focus on responsible product steward-
ship for the ﬂavours that are essential to create consumer-relevant
e-liquids. We suggest an approach to toxicological risk assessment
of ﬂavours that takes into account the in-going ﬂavour ingredients
and constituents and the identiﬁcation, measurement and risk
assessment of any potential thermal breakdown and reaction
products.2. Screening and risk assessments
2.1. Aerosol versus e-liquid
The aerosolisation process involves a brief heating period dur-
ing every puff of an e-cigarette. Published data around heater oper-
ating temperatures are scarce, but estimates have ranged from 40–
65 C (Bertholon et al., 2013; Westenberger, 2009) to 170–180 C
(Talih et al., 2015), and even up to 350 C or higher in the absence
of e-liquid (Schripp et al., 2013). Regardless of the exact operating
temperatures of individual vaping products under speciﬁc condi-
tions, a heating period introduces the potential for pyrolysis of
compounds and endothermic reactions between them.
Additionally, the compounds can respond in varying degrees to
the different processes involved in aerosolisation, such as evapora-
tion and condensation. Together these factors might result in
changes to the composition of the aerosol versus that of the
e-liquid. Appropriately sensitive measurement of the aerosol,
therefore, is required for the risk assessment to take into account
potential thermal breakdown and reaction products of ﬂavouring
ingredients (Fig. 1).2.2. Screening of in-going ingredients
The ﬁrst screening step for in-going ingredients relates to the
purity of the compounds (Fig. 1). As a practical way of minimising
risks from potential contaminants in ingredients, we suggest that
only food-grade ﬂavouring ingredients are used to provide some
reassurance on purity and systemic toxicity. Food ﬂavours, how-
ever, are not normally assessed for inhalation exposures and fur-
ther safety assurance is required.
A toxicological risk assessment also requires knowledge
through full quantitative disclosure of the individual ingredients
and constituents in e-liquid. This requirement sounds obvious,
but besides the commercial sensitivity of ﬂavour recipes and
sub-ﬂavours, challenges surround consistency and identiﬁcation
of constituents, especially for ingredients of natural origin. The
compositions of naturals vary dependent on biological and geo-
graphical origins and weather and other environmental factors
affecting growth and harvest, and can change over time. Thus,
using only naturals that are approved food ﬂavourings ensures that
speciﬁc limits have been placed on constituents of known toxico-
logical concern. An example of such restrictions can be found in
article 6 of the European food ﬂavouring regulations (European
Parliament and the Council, 2008b).2.2.1. Ingredients classed as carcinogenic, mutagenic or toxic to
reproduction
Exclusion of ingredients from use if they have properties known
to be carcinogenic, mutagenic or toxic to reproduction (CMR) is
considered a basic safety precaution. In general, use of only
food-grade ﬂavourings should already have ensured they are not
CMR, however, because classiﬁcation criteria can differ per region
and several food ﬂavourings have been grandfathered on toapproved lists on the basis of historic use, exceptions may exist.
Therefore our proposed screening criteria also explicitly exclude
any ingredients classed as group 1, 2A or 2B carcinogens in the
International Agency for Research in Cancer classiﬁcation, as well
as any classiﬁed as CMR by the US Food and Drug Administration
(FDA) or if a harmonised European classiﬁcation exists.
Additionally, ingredients that appear on the REACh list for sub-
stances of very high concern (ECHA (European Chemicals
Agency), 2014) for human toxicity reasons should also be avoided,
as should all compounds that have been identiﬁed by the FDA as
‘‘harmful and potentially harmful compounds’’ or HPHC in a
tobacco smoke context (Food and Drug Administration (FDA),
2012). For ingredients that are not evaluated or classiﬁed or where
only a manufacturer’s self-notiﬁed classiﬁcation exists, a
weight-of-evidence approach is recommended that applies criteria
to the data as described by the Globally Harmonized System of
Classiﬁcation.2.2.2. Respiratory sensitisers
Some discussion has taken place about restricting the inclusion
of contact allergens in e-liquids. An evaluation process has been
proposed that includes a tolerable no effect level of 1000 ppm in
e-liquids, belowwhich the chance of induction of contact sensitisa-
tion and eliciting effects in pre-sensitised people is considered tol-
erable (Costigan, 2014). However, the situation is different for
respiratory sensitisation. If e-liquids were to contain respiratory
sensitisers (i.e. type I allergens and causative agents of immediate
hypersensitivity), inhalation exposure over time could lead to
IgE-mediated responses, such as are experienced with hay fever
and occupational asthma (e.g. perennial rhinitis, eczema, breathing
difﬁculties and bronchoconstriction). Although extremely rare, in
the very worst case, people might experience anaphylactic
responses, including death. The potential severity of symptoms
related to respiratory allergens, therefore, sets these substances
apart from those causing the more common contact sensitisation.
Additionally, although contact sensitisation is a well-understood
process with recognised, robust hazard identiﬁcation tests and
quantitative risk assessment processes (Api et al., 2008; OECD,
2010; United Nations, 2013), no validated hazard identiﬁcation
tests and quantitative risk assessment processes exist for respira-
tory sensitisation and the recommended approach relies on a
weight of evidence evaluation (ECETOC, 1999; ILSI HESI, 2014;
United Nations, 2013). Some tests are in use for hazard identiﬁca-
tion, such as the measurement of immunoglobulin E (IgE) in mice
and speciﬁc guinea pig pulmonary responses (Briatico-Vangosa
et al., 1994; Kimber et al., 1996; Pauluhn, 1996), but their applica-
bility is restricted to certain chemical classes of compounds.
Hazard identiﬁcation and the derivation of tolerable doses are
therefore based on a weight-of-evidence approach, where occupa-
tional experience especially can form an important hazard alert
function. On top of the identiﬁcation uncertainties, several respira-
tory sensitisers have very low derived no-effect levels, leading to
occupational exposure guidelines being measured in lg/m3 for
anhydrides (WHO, 2009), and even 5–60 ng/m3 for several
enzymes (AISE Enzymes Occupational Exposure Working Group,
2013).3. Review of existing toxicological evidence
If ﬂavouring ingredients pass the screening stage, a review of
the existing toxicological data should follow. This approach will
contribute to identifying any evidence of inhalation-speciﬁc issues
that might make a compound unsuitable for use in an inhala-
tion product. An example is the potential for diacetyl and
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Fig. 1. Flavour ingredient screening and risk assessment process ﬂow. Abbreviations: CMR – carcinogenic, mutagenic or toxic to reproduction; GC/MS – gas
chromatography/mass spectrometry.
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et al., 2014; Farsalinos et al., 2014; Halldin et al., 2013).
Much of the traditional ﬂavour testing has focussed on oral
exposure. This can provide valuable information with regards to
potential systemic toxicity of the ﬂavour but does not provide
information on potential effects on the respiratory tract and does
not take into account any possible effect from the brief heating
the ﬂavour undergoes in the aerosolisation process. In that context,
it is worth noting hundreds of ﬂavours have been tested via the
inhalation route as part of cigarette exposures (Baker et al.,
2004a,b,c; Gaworski et al., 2011; Renne et al., 2006;
Vanscheeuwijck et al., 2002). Individual ﬂavours or groups of ﬂa-
vours were added to the tobacco rod and the resultant smoke
was analysed for priority smoke constituents and tested in several
in vitro tests as well as 90-day rat inhalation studies. In general,
addition of the ﬂavours had no effect on, or reduced the levels of
most of the measured smoke constituents. Even in the few
instances where some increases in smoke constituents were
observed, these changes did not affect the smoke’s in vitro cytotox-
icity, in vitro bacterial mutagenicity, in vitro mammalian genotox-
icity or inhalation toxicity. Because this testing used the
inhalation route of exposure and included heating of the ﬂavours,
it provides some qualitative reassurance on those ﬂavours that
can add to the weight of evidence evaluation of a ﬂavour com-
pound for use in an electronic cigarette. However, the ﬂavours
were tested against a background of cigarette smoke, which itself
causes toxicity, and the temperatures reached in a burning cigar-
ette are many hundreds of degrees centigrade higher than that of
vaping products. Therefore the main value of this vast body of data
is as a source of potential alerts that a ﬂavour may require further
investigation if some equivocal or adverse effect were seen. For
example, at very high inclusion levels (10% of the tobacco rod),
the addition of spearmint oil resulted in equivocal results, the
depression of body weight gains and increased atrophy of olfactory
epithelia in male rats only (Coggins et al., 2011a). In contrast, some
other ingredients, most notably glycerol triacetate and lactic acid,
have been seen to ameliorate the inhalation toxicity traditionally
seen from cigarette smoke (Coggins et al., 2011b,c). These effects
may well be mediated via interactions that are not relevant to vap-
ing products, but they act as an alert that further investigation is
required.
Where there is no inhalation data that is suitable for hazard
assessment or hazard characterisation of the ingredient itself, local
responses observed via other exposure routes might help inform
the risk assessment in a qualitative way. For example, if a com-
pound has shown irritation potential via dermal and/or ocular
exposures, it is likely that respiratory irritation will also be a rele-
vant end point. Additionally, relevant toxicity data on structural
analogues might be available. Considerations from scientiﬁc bodies
in establishing occupational exposure guidelines can also be very
helpful in deliberating the weight of evidence, which is needed
to integrate the resulting multitude of, largely qualitative,
information.
Within a weight of evidence approach, to help strengthen ratio-
nales for quantitative interpretation of the information, looking at
the rules for mixture classiﬁcations laid down in the European
Classiﬁcation Labelling and Packaging regulations can also be help-
ful (European Parliament and the Council, 2008a). The regulation
includes generic cut-off concentrations that are deﬁned per toxic
end point. If compounds are present below the levels given, their
presence does not need to be taken into account when establishing
the hazard classiﬁcation of the overall mixture via the calculation
route. This effectively presents a practical rule of thumb, with
some regulatory support, below which a compound’s toxicity is
not expected to contribute signiﬁcantly to the overall toxicity of
that mixture.4. Use of toxicological thresholds of concern
Some food-grade ﬂavouring ingredients have surprisingly lit-
tle to support them other than generally recognised as safe
(GRAS) status, which can on occasion rely only on historic use
free from known issues. Such qualitative support does not easily
translate into supportable levels in product. In that context,
another useful threshold concept that can be helpful when there
is a lack of data on local and systemic toxicity is the toxicological
threshold of concern (TTC). The TTC concept and approach have
recently been reviewed by several regulatory authorities and
advisory organs (EFSA Scientiﬁc Committee, 2012; Nielsen and
Larsen, 2011; Scientiﬁc Committee on Consumer Safety (SCCS)
et al., 2012). Although the concept was originally proposed in
the context of contaminant risk assessment and prioritisation,
much extension and validation work has since been published,
and TTC is now recommended for chemical risk assessment in
many situations beyond contaminants (see Tables 1 and 2 for
details).
We propose TTC as a suitable concept for risk assessing two
classes of vaping aerosol compounds:
(1) Ingredients where the supporting toxicological data is qual-
itative and does not lend itself to the quantitative derivation
of a DNEL;
(2) Thermal degradation and reaction products of ingredients,
as long as the compounds do not belong to the classes of
chemicals for which the TTC approach is deemed inappropri-
ate, as speciﬁed in (Scientiﬁc Committee on Consumer Safety
(SCCS) et al., 2012). A distinction is made between ingredi-
ents and thermal degradation and reaction products,
because ingredients will be well deﬁned compounds for
which CMR hazards have already been excluded (see
Section 2) and for which there will usually be toxicological
data or other product experience available (as per
Section 3). In contrast, for low-level contaminants, chemical
identiﬁcation and toxicological data might be limited and no
hazard screening has taken place.
Several proposals for inhalation TTCs have been made
(Table 2). They differ largely by the type of compound that
was in the databases used to derive the no observed effect
levels/no observed effect concentrations from, viz. industrial
chemicals (Escher et al., 2010, 2013), air pollutants or industrial
chemicals with inhalation occupational exposure guidelines
(Drew and Frangos, 2007) or ingredients of consumer aerosol
products (Carthew et al., 2009). The TTCs derived from industrial
chemicals and organic air pollutants were based on compounds
generally considered to be potentially toxic. In contrast, ﬂavour-
ing ingredients will already have been subject to the speciﬁc
selection criteria described earlier. The more relevant TTCs for
this group of compounds, therefore, are those derived from con-
sumer aerosol products. Carthew et al. derived TTCs for systemic
and local effects from inhalation exposure (Carthew et al., 2009).
For compounds in Cramer classes 1 and 3, the TTCs derived for
systemic effects were lower than those for local effects (class 1
TTC for systemic effects 980 lg/day vs 1400 lg/day for local
effects; class 3 TTC for systemic effects 170 lg/day vs 470 lg/day
for local effects). We propose that the use of the most stringent
of the TTCs derived from inhalation studies are appropriately
conservative for risk assessment of ﬂavouring ingredients for
e-cigarettes (i.e. 980 lg/day for Cramer class 1 compounds and
170 lg/day for Cramer class 3 compounds). Because the database
did not contain sufﬁcient Cramer class 2 compounds to derive a
TTC, the conservative approach is taken of applying the Cramer
class 3 TTC to Cramer class 2 compounds.
Table 1
Overview of oral TTCs.
Source Area of use TTC Comments Refs.
COM 0.15 lg/day For genotoxins and mutagens COM (2012)
International Life Sciences
Institute
Food 0.15 lg/day For compounds with structural alerts for genotoxicity Kroes et al.
(2004)
FDA Threshold of
Regulation
Food
contact
articles
1.5 lg/day
or 0.5 ppb
Substances found in food at 0.5 ppb (derived from 1.5 lg/day) or less, do not require
regulation as food additives
Applied to substances regardless of their toxicity proﬁle (i.e. could be a carcinogen)
Based on oral data on 709 carcinogens, resulting in 96% probability that cancer life time
risk is less than 106, assuming 10% probability of the unknown compound being a
carcinogen, derived in (Munro, 1990)
FDA (1995)
European Medicines
Agency and ICH
proposal
Human
medicines
1.5 lg/day For non-threshold, genotoxic contaminants
Estimated 105 life time cancer risk considered acceptable rather than 106 due to
anticipated beneﬁts from medicines
EMEA (2006)
and ICH
(2013)
International Life Sciences
Institute
Food
(JECFA)
1.5 lg/day For non-genotoxins that are not metals, metal-containing compounds, polyhalogenated
dibenzodioxins, -dibenzofuran, -biphenyls, aﬂatoxin-like, azoxy- or N-nitroso- compounds
Kroes et al.
(2004)
International Life Sciences
Institute
Food 18 lg/day For organophosphates Kroes et al.,
(2004)
FDA threshold of
regulation proposal (not
adopted)
Food
contact
articles
45 lg/day For compounds without structural alert for carcinogenicity, regardless of the results of
Ames testing, with LD50 > 1000 mg/kg body weight per day
Based on:
Linear, low dose extrapolation to a less than 106 cancer life time risk using the lowest
TD50 – value for 709 rodent carcinogens
Oral, reproductive toxicant data on 3306 compounds
Other repeat dose toxicology studies on 2542 compounds
Cheeseman
et al. (1999)
International Life Sciences
Institute
Food
(JECFA and
EFSA)
90 lg/day For compounds of structural Cramer class 3 that are not genotoxins, metals, metal-
containing compounds, polyhalogenated dibenzodioxins, -dibenzofuran, -biphenyls,
aﬂatoxin-like, azoxy- or N-nitroso- compounds
Based on 100-fold safety factor times 5th percentile of NOEL distribution of the most
sensitive species, sex and (non-carcinogenicity) toxicological end point for the compounds
of this Cramer class in a database containing oral data on 613 substances
JECFA use also takes into account any available information on structure-activity
relationships, metabolism and intake and toxicology data on groups of structurally related
compounds
Kroes et al.
(2004)
International Life Sciences
Institute)
Food
(JECFA and
EFSA)
540 lg/day For compounds of structural Cramer class 2. Otherwise same comments as for 90 lg/day
TTC
Kroes et al.
(2004)
International Life Sciences
Institute
Food
(JECFA and
EFSA)
1800 lg/day For compounds of structural Cramer class 1. Otherwise same comments as for 90 lg/day
TTC
Kroes et al.
(2004)
Abbreviations: COM – UK Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment. TTC – toxicological threshold of concern. JECFA – Joint
FAO/WHO Expert Committee on Food Additives. EFSA – European Food Safety Agency. ICH – International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. LD50 – median lethal dose. TD50 – median toxic dose. NOEL – no observed effect level.
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As per the process described in Fig. 1, the aerosol needs to
be measured to identify any potential reaction and breakdown
products of ﬂavours. Emerging data (internal, unpublished) indi-
cate that vaping the same e-liquid in different devices can result
in quite different aerosols. This is no surprise to vapers who are
well aware that different devices require different types of
e-liquids and a variety of vaping websites provide user experience
on the kind of vapour produced by different e-liquids in different
types of vaping devices.
Any ﬂavour related new compounds can be seen as aerosol con-
taminants and should be risk assessed for inhalation using the
same standard principles as applied to the ingoing ingredients.
For example, common ﬁndings are the formation of acetals from
propylene glycol and ﬂavours with an aldehyde moiety (Costigan
et al., 2014). Such acetals are sensitive to hydrolysis and will most
likely hydrolyse back into the ingoing ﬂavour and propylene glycol
in the high humidity environment in the respiratory tract or as part
of the metabolic pathway.
However, one big difference between ingoing ﬂavour ingredi-
ents and potential thermal or reaction products is that, where com-
pounds with CMR properties and respiratory toxicity have been
excluded from use as ingredients, no such restrictions can be
applied to these contaminants that might be found in the aerosol.
Therefore, if the risk assessment of the compound relies on a TTCapproach, use of TTCs derived from more conservative databases
than that used for ﬂavouring ingredients, is appropriate. The
inhalation TTCs proposed on the basis of industrial chemical and
air pollutant databases show substantial variation (Table 2). If
the type of chemicals is not restricted to those suitable for use in
aerosol consumer products, the breadth of potential chemical
classes is widened notably. Relative to that breadth, limited num-
bers of chemicals are included in the databases on which the pro-
posed TTCs are based. For inhalation exposures, the scientiﬁc
consensus is therefore that route-to-route extrapolation from
well-substantiated oral values is the preferred option (Hollnagel
et al., 2013; Schilter, 2013; Scientiﬁc Committee on Consumer
Safety (SCCS) et al., 2012; Williams et al., 2013). A suitable safety
factor needs to be derived, therefore, to derive contaminant inhala-
tion thresholds based on the well-established oral TTCs.
In this context, it is worth reiterating the observation that for
Cramer class 1 and 3 aerosol ingredients, the TTCs derived from
inhalation data for systemic effects were lower than those for local
effects (Carthew et al., 2009). This ﬁnding is in contrast to the
assumption sometimes made that the respiratory tract could have
a high sensitivity to local effects and that they would therefore be
likely to dictate the overall TTC. This hypothesis was recently
investigated by reviewing inhalation studies from an expanded
RepDose database (296 compounds) for local versus systemic No
Observed Effect Concentration (NOEC) values and local versus the
most sensitive NOEC regardless of toxic end point. This
Table 2
Overview of inhalation TTCs.
Area of use TTC Comments Refs.
Organic air
toxins
0.7 lg/day or 0.03 lg/m3 Based on recalculating the US FDA oral TTC of 0.02 lg/kg body weight per day for
unknown compounds (including carcinogens), to continuous, environmental
inhalation exposure, assuming 50% of the oral TTC, 70 kg body weight and 20 m3
inhalation rate/day
Validated by comparing against 1857 air guideline values: only 4 (i.e. 0.2%) were
below the concentration of no toxicological concern
Where these air reference values were occupational exposure guidelines, they were
adjusted for exposure duration (continuous instead of 8 h/day, 5 days/week) and a
safety factor 10 was used to account for greater variation in sensitivity of general
population versus healthy workers
Drew and Frangos (2007)
Heat-not-burn
tobacco
product
1.5 lg/day RJ Reynolds Eclipse risk assessment R.J. Reynolds Tobacco
Company (1988)
Cigarettes 1.5 lg/day or 0.05 lg/cig or
0.025 ppm cut ﬁller
concentration
Phillip Morris International threshold for substances (ingredients and contaminants)
below which they do not require evaluation. Based on FDA threshold of 1.5 lg/day,
assuming 40 cigarettes per day, 0.8 g of tobacco, 100% transfer into smoke,
mainstream to side stream ratio of 80:20 and 100% absorption by the lung
Dempsey et al. (2011) and
Phillip Morris USA (2009)
Industrial
chemicals
2.7 lg/day or
2.3 ⁄ 105 ppm/day
Cramer class 3 compounds, excluding genotoxins and organophosphates
Based on data on 250 Cramer class 1 or 2 compounds in RepDose database
Escher et al. (2013)
Industrial
chemicals
4 lg/day or
2.4 * 105 ppm/day
Cramer class 3 compounds, excluding genotoxins and organophosphates
Based on data on 122 compounds in RepDose database
Escher et al. (2010)
Consumer
aerosol
products
170 lg/day Cramer class 3 compounds, excluding genotoxic carcinogens. Based on 92 rat
inhalation studies. If the study was less than life time, adjustment factors as per
REACh TGD were applied
Based on systemic effects, local effects of same group would have led to TTC of
470 lg/day (i.e. systemic TTC will protect for that as well)
Carthew et al. (2009)
Industrial
chemicals
180 lg/day Cramer class 1 compounds, excluding genotoxins and organophosphates
Based on data on 122 compounds in RepDose database
Escher et al. (2010)
Consumer
aerosol
products
980 lg/day Cramer class 1 compounds, excluding genotoxic carcinogens. Based on 92 rat
inhalation studies. If the study was less than life time, adjustment factors as per
REACh TGD were applied
Based on systemic effects, local effects of same group would have led to TTC of
1400 lg/day (i.e. systemic TTC will protect for that as well)
Carthew et al. (2009)
Industrial
chemicals
3979 lg/day or
4.7 * 102 ppm/day
Cramer class 1 compounds
Based on data on 250 Cramer class 1 or 3 compounds in RepDose database
Escher et al. (2013)
Abbreviations: TTC – toxicological threshold of concern. FDA – Food and Drug Administration. TGD – technical guidance document.
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dissimilar and did not conﬁrm a particular sensitivity of the respi-
ratory tract to local end points (Escher et al., 2013).
The Cramer class 1 TTC derived from inhalation data on con-
sumer aerosol ingredients is approximately half that of the tradi-
tional Cramer class 1 TTC derived from oral data (i.e. 970 lg/day
vs 1800 lg/day). For Cramer class 3 compounds the
inhalation-derived TTC was higher than that derived from oral
data, but would have been highly inﬂuenced by the aerosol data-
base having excluded the most toxic of the Cramer class 3 com-
pounds. The factor 2 difference found in the Cramer class 1
comparison is in line with the default oral to inhalation bioavail-
ability extrapolation recommended by REACh (ECHA (European
Chemicals Agency), 2012). It is also qualitatively compatible with
considerations expressed at an international workshop in which
extrapolation of oral TTCs to inhalation values were discussed.
On the one hand it was noted that TTC values for inhalation expo-
sures might be expected to be lower than those from oral expo-
sures due to high absorption and low ﬁrst-pass detoxiﬁcation on
uptake from the lungs. On the other hand, however, it was recom-
mended an appropriate form of inter-species scaling should be
used instead of the default factor of 10 used in deriving the oral
values (Dewhurst and Renwick, 2013), as in the risk assessment
guidance, such as that from REACh (ECHA (European Chemicals
Agency), 2012), which will at least partially compensate for the
expected higher absorption and lower detoxiﬁcation effects in
deriving human inhalation TTCs from the oral data.
In addition to route extrapolation considerations, duration of
exposure needs to be taken into account. As a default, comparisons
of chronic oral to chronic inhalation exposure convert the data toexposure for 24 h/day. This is unrealistic for exposure from vaping
products. If we conservatively assume that approximately half of
a user’s waking hours are spent vaping, exposure would be for 8 h
instead of 24 h. A combined duration–route extrapolation factor
of 0.67 (i.e. 8/24 * 2) would, therefore, be appropriate. However,
because each of the inhalation databases used in the comparisons
had its own limitations, we propose an oral to inhalation extrapola-
tion factor of 1 for TTCs for aerosol contaminant risk assessment for
vaping products. As a result, the TTCs established for oral exposures
(Kroes et al., 2004), including the restrictions on chemical class, can
be directly applied to contaminant aerosol risk assessment. As with
ingredients, the number of Cramer class 2 compounds evaluated is
highly limited and, therefore, we suggest that Cramer class 3 TTC
values be applied to Cramer class 2 contaminants. Thus, a TTC of
1800 lg/day is proposed for Cramer class 1 compounds, and a TTC
of 90 lg/day for Cramer class 2 and 3 compounds.
In the ﬁrst instance it seems incongruous that the TTC proposed
for Cramer class 1 contaminants (1800 lg/day) is higher than that
proposed for Cramer class 1 ingredients (970 lg/day). However, in
the light of the exposure estimates with which these TTCs will be
used, the difference becomes justiﬁable. Ingredients can be
expected to consistently end up in the vaping aerosol and, there-
fore, the consumer will be exposed with every puff. In contrast,
the occurrence and level at which reaction and thermal breakdown
products might occur in the aerosol will vary. For example, storage
and transport conditions of the e-liquid and how long it has been
open to the air will inﬂuence levels of reaction products.
Potential thermal degradation can be inﬂuenced by the length of
a puff, the air ﬂow of the individual puff, how recently the coil
has been replaced, etc. As a default, good risk assessment practice
S. Costigan, C. Meredith / Regulatory Toxicology and Pharmacology 72 (2015) 361–369 367dictates that worst case, measured peak exposures should be the
value from which to estimate realistic worst case consumer expo-
sures. As a result of the intermittent presence of contaminants ver-
sus the consistent presence of ingredients, chronic exposure
estimations derived from peak exposures will thus be more of an
overestimate for aerosol contaminants than for ingredients. The
TTCs have been based on chronic, low-level exposures. This is an
exposure pattern for which the average exposures over time are
generally more relevant than peak exposures. Therefore, a higher
TTC can be applied to the estimated worst case exposures derived
for contaminants from the aerosol measurements than that esti-
mated for ingredients.
The TTC concept is also helpful in the practical question of how
accurate the analytical data should be that inform the risk assess-
ment of the aerosol contaminants. Daily exposure to an unknown
contaminant is generally taken to be tolerable at levels lower than
1.5 lg per day (Table 1). We propose the limit of detection for the
general gas chromatography scan used to identify if there are any
contaminants in the aerosol, is based on this concept. For vaping
products, the estimated daily number of puffs has been reported
as on average 120 puffs/day (25th percentile 80, 75th percentile
200), based on online questionnaire data from 3587 participants,
whose median duration of e-cig use was 3 months (Etter and
Bullen, 2011). Older internet survey data from the same team indi-
cated the 81 ever-users of e-cigarettes drew a median of 175 puffs
per day (Etter, 2010). A reasonably conservative estimate, there-
fore, would be 300 puffs/day. To detect an estimated intake of
1.5 lg/day over 300 puffs/day, requires a limit of detection of
approximately 1500 ng/300 puffs = 5 ng/puff.
Application of the TTC approach to aerosol contaminant risk
assessment is only one option. Dependent on the available data
and case-by-case considerations, other risk assessment approaches
can be applied instead. For example, the estimated exposure level
can be compared to those from other exposures that are considered
acceptable or tolerable, such as environmental background expo-
sures or exposures via the diet. Comparisons can also be made with
exposures fromappropriate comparatorproducts. Currently thevast
majority of e-cigarette users start vaping when they are smokers,
and the vaping generally results in smoking cessation or reductions
in cigarette consumption (ASH (Action on Smoking and Health),
2014; Biener and Hargraves, 2014; Brown et al., 2014; Etter and
Bullen, 2011). At least some of the small percentage of
never-smokers who vape are thought to have also considered cigar-
ette smoking but decided on vaping instead. Thus, the percentage of
never smokers among e-cigarette users, especially those using them
as a smoking replacement, could increase. Overall, for most estab-
lished users today, vaping is a cigarette replacement activity and
therefore exposures from cigarettes are a reasonable comparator.
However, this comparator should only be applied to unavoidable
aerosol contaminants, such as the thermal breakdown and reaction
products from the humectants and nicotine. Although ﬂavours are
an essential part of an e-liquid, no one ﬂavour is irreplaceable.
Supportability on the grounds of resulting in less exposure than
cigarettes should therefore not be applied to individual ﬂavouring
compounds. For ﬂavourings, a risk assessment could, for example,
support the ingredients based on an absence of effects over and
above those seen with a ﬂavour-free version of the same e-liquid
aerosol. An appropriate comparator might also be the range of com-
pounds measured in aerosol from good-quality commercially avail-
able products, but the market place is currently mixed and quality
might be hard to deﬁne.
6. Conclusions
Flavouring ingredients are an essential part of vaping products,
but inhalation data suitable for setting supportable levels ine-liquids, exist on only a limited number of compounds. We there-
fore suggested a practical approach to risk assessment of in-going
ﬂavouring ingredients in e-liquid and potential thermal break-
down and reaction products in the aerosol (i.e. contaminants).
We recommend excluding ﬂavouring ingredients with CMR prop-
erties or respiratory sensitisation properties (Fig. 1). Additionally,
to provide a base level of reassurance on systemic toxicity and
restrict the level of potentially toxic contaminants, we recommend
that only food-grade ﬂavourings are used. Risk assessment should
take into account the published data on ingredients to help exclude
compounds with known speciﬁc inhalation issues. The application
of inhalation TTCs can be useful for compounds with limited toxi-
cological data on which to base a quantitative inhalation risk
assessment. The most stringent of the TTCs derived from inhalation
data on consumer aerosol ingredients are proposed as applicable
for ﬂavour ingredient risk assessment, that is, 970 lg/day for
Cramer class 1 compounds and 170 lg/day for Cramer class 2
and 3 compounds. For aerosol contaminants, TTCs derived from
other databases are more relevant and other exposure considera-
tions apply. Therefore, a TTC of 1800 lg/day is considered appro-
priate to apply to worst-case exposure estimates for Cramer class
1 contaminants and 90 lg/day for Cramer class 2 and 3 contami-
nants. Risk assessment also needs to be informed by appropriate
analytical measurements to identify the potential aerosol contam-
inants. We suggest a gas chromatographic technique is employed
with a limit of detection of approximately 5 ng/puff.Conﬂict of interest
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